Top
Novartis gene therapy approved, but will come at cost of more than $2 million - Healing Genes
1077
post-template-default,single,single-post,postid-1077,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2078

Novartis gene therapy approved, but will come at cost of more than $2 million

Share on facebook
Share on google
Share on twitter
Share on linkedin

Babies born with a severe form of a rare genetic condition known as spinal muscular atrophy almost always die before their second birthday. A gene therapy approved Fridayby the Food and Drug Administration promises to change that, offering a potential one-time fix for the genetic deficiency behind the neuromuscular disease.

Zolgensma, as the treatment is called, is only the second gene therapy for an inherited disorder to be cleared for commercial use in the U.S. Its keenly awaited approval marks another milestone for a fast-moving field, and validates the decision by Novartis last year to acquire its developer, the biotech company AveXis, for $8.7 billion.

The therapy is also notable for its price. At $2.125 million per dose, Zolgensma is the most expensive treatment ever brought to market. Novartis intends for that price to be paid in installments of $425,000 a year for five years.

Click here for the full story: https://www.biopharmadive.com/news/novartis-gene-therapy-zolgensma-approved-fda/554961/

More to explorer

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader

CRISPR treatment inserted directly into the body for first time

A person with a genetic condition that causes blindness has become the first to receive a CRISPR–Cas9 gene therapy administered directly into their body. The treatment is part of a landmark clinical trial to test the ability of CRISPR–Cas9 gene-editing techniques to remove mutations that

No Comments

Sorry, the comment form is closed at this time.